Chronos Archive seal
The Human Record

Alan Turing

Case HR-ML007 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
23 June 1912 – 7 June 1954
Synthetic DOB
1985-06-23
Index visit
2026-04-14 at age 40
Synthetic MRN
HR-ML007-SYN

Teaching objective: Recognize and manage the harm of high-dose estrogen given to a 40-year-old gay man without his free and informed consent: evaluate gynecomastia as the EAA 2019 guideline advises (history, breast and testicular examination, testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests, scrotal ultrasound, breast imaging only if the examination is equivocal), name the cause as iatrogenic, stop the exposure, monitor recovery of the hypothalamic-pituitary-gonadal axis without testosterone therapy while it recovers, protect bone health, and offer surgery if gynecomastia persists; treat a moderate depressive episode with measurement-based care, gay-affirming psychotherapy, and an antidepressant only if he chooses one, with a structured suicide-risk assessment, a safety plan, and the 988 Lifeline; offer HIV and STI testing and a PrEP discussion as routine adult care with his consent; and practise LGBTQ-affirming primary care. Sexual orientation is recorded as part of his social history, never as a problem, and every test and treatment requires his free, informed consent.

Historical timeline

DateEventClaims
23 June 1912Born in Paddington, London.CLM-0001
1951Training for long-distance running around Wilmslow.CLM-0002
31 March 1952Tried for gross indecency; accepts a year of oestrogen treatment instead of prison; loses his security clearance.CLM-0003, CLM-0004, CLM-0005, CLM-0007, CLM-0008
November 1952Decides to see a psychiatrist again and begins Jungian analysis.CLM-0006
7 June 1954Dies at his home in Wilmslow; the inquest verdict, suicide, is later disputed.CLM-0009, CLM-0010, CLM-0011
10 September 2009The Prime Minister apologises on behalf of the government.CLM-0012
24 December 2013Posthumous royal pardon.CLM-0013

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Alan Mathison Turing was born on 23 June 1912 in a nursing home in Paddington, London. confirmed Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports
O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics supports
D He was a long-distance runner: he built his strength in cross-country running, was known for running to scientific meetings, and in 1951 was still training for long-distance running on the roads around Wilmslow, where he had bought his first house. confirmed Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports
Hodges A. The Alan Turing Internet Scrapbook: Non-linear Life supports
D After reporting a burglary at his home in 1952 he was arrested over a relationship with another man and tried on 31 March 1952 for "gross indecency"; rather than go to prison he accepted, for a year, oestrogen treatment intended to neutralise his libido.
Same-sex relations between men were then a crime in England; the treatment was imposed as the alternative to a prison sentence, not chosen as care.
confirmed Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports
O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics supports
Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports
D His biographer Andrew Hodges writes that the drug was probably stilboestrol, a synthetic oestrogen; the 2009 government statement and other sources describe the treatment as a series of injections of female hormones.
The exact preparation and route are not settled in the sources read.
probable Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports
Gordon Brown issues apology for treatment of Alan Turing supports
Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports
D Hodges describes the injurious and humiliating effect of the hormones on his body; it is often repeated that the treatment made him grow breasts, though he is known to have mentioned this only once.
Breast growth (gynecomastia) is an expected effect of high-dose oestrogen in a man.
probable Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports
Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports
D In a letter of 23 November 1952 he wrote that he had decided to have "another, and rather more co-operative go at a psychiatrist"; this was Jungian analysis with a refugee analyst, and he became very enthusiastic about it and wrote down all his dreams.
Seeking analysis is documented; no psychiatric diagnosis is recorded in the sources read.
confirmed Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports
D His conviction led to the removal of his security clearance, so that he could no longer work for Government Communications Headquarters as he had since the war. confirmed Royal pardon for WW2 code-breaker Dr Alan Turing supports
D After the trial he returned to a wide range of academic work, including morphogenesis, quantum theory, and relativity, at Manchester University. confirmed O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics supports
Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports
D He died on 7 June 1954 at his home in Wilmslow, Cheshire, of cyanide poisoning, and the coroner's verdict was suicide. confirmed Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports
O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics supports
Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports
R In 2012 Professor Jack Copeland argued that the inquest evidence would not today support a suicide verdict, that friends had described him as cheerful in the days before he died, and that accidental inhalation of cyanide from a home electrolysis experiment was equally likely.
A retrospective challenge to the inquest finding; the cause of death remains disputed.
disputed Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports
R Hodges judges it more credible that Turing ended his own life and arranged matters so that it could be taken for an accident.
A biographer's interpretation; it conflicts with CLM-0010.
disputed Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports
Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports
D On 10 September 2009 the Prime Minister apologised on behalf of the British government, calling his treatment inhumane and describing his sentence as chemical castration by a series of injections of female hormones, accepted as the alternative to prison. confirmed Gordon Brown issues apology for treatment of Alan Turing supports
D On 24 December 2013 he received a posthumous royal pardon; the Justice Secretary called the conviction unjust and discriminatory, and the Prime Minister said the sentence of chemical castration had caused physical and emotional damage. confirmed Royal pardon for WW2 code-breaker Dr Alan Turing supports
R The roster lists depression as a primary condition; the sources read document his prosecution, the hormone treatment, and his decision to seek Jungian analysis, but record no diagnosis of depression, so a depressive illness is a retrospective interpretation.
Retrospective and uncertain; it must not be read as a documented diagnosis.
possible HISTMED Master Roster v3 supports
Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment active confirmed both_with_link CLM-0005
S Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue resolved confirmed active CLM-0003
S Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment active confirmed both_with_link CLM-0003, CLM-0004, CLM-0005, CLM-0012, CLM-0013
S Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) active confirmed both_with_link CLM-0006, CLM-0014
S Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) resolved confirmed active
S Right lateral ankle sprain while trail running, able to bear weight, Ottawa ankle rules negative; resolved resolved confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-04-14 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 15 http://loinc.org · 44261-6
S 2026-04-14 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 8 http://loinc.org · 70274-6
S 2026-04-14 Total score [AUDIT-C] 2 http://loinc.org · 75626-2
S 2026-04-14 Testosterone [Mass/volume] in Serum or Plasma 112 ng/dL (low)
Reference 264-916 ng/dL
http://loinc.org · 2986-8
S 2026-04-14 Estradiol (E2) [Mass/volume] in Serum or Plasma 148 pg/mL (high)
Reference 7.6-42.6 pg/mL
http://loinc.org · 2243-4
S 2026-04-14 Lutropin [Units/volume] in Serum or Plasma 0.3 m[IU]/mL (low)
Reference 1.7-8.6 m[IU]/mL
http://loinc.org · 10501-5
S 2026-04-14 Follitropin [Units/volume] in Serum or Plasma 0.4 m[IU]/mL (low)
Reference 1.5-12.4 m[IU]/mL
http://loinc.org · 15067-2
S 2026-04-14 Sex hormone binding globulin [Moles/volume] in Serum or Plasma 88 nmol/L (high)
Reference 16.5-55.9 nmol/L
http://loinc.org · 13967-5
S 2026-04-14 Prolactin [Mass/volume] in Serum or Plasma 21.6 ng/mL (high)
Reference 4-15.2 ng/mL
http://loinc.org · 2842-3
S 2026-04-14 Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma 1 m[IU]/mL
Reference <=3 m[IU]/mL
http://loinc.org · 21198-7
S 2026-04-14 Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 2.6 ng/mL
Reference <=8.3 ng/mL
http://loinc.org · 1834-1
S 2026-04-14 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-04-14 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 2026-04-14 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-04-14 Creatinine [Mass/volume] in Serum or Plasma 0.96 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-04-14 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 102 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-04-14 Thyrotropin [Units/volume] in Serum or Plasma 1.9 mIU/L
Reference 0.4-4 mIU/L
http://loinc.org · 3016-3
S 2026-04-14 Hemoglobin [Mass/volume] in Blood 13 g/dL (low)
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 2026-04-14 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 22 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-04-28 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 14 http://loinc.org · 44261-6
S 2026-04-28 Estradiol (E2) [Mass/volume] in Serum or Plasma 46 pg/mL (high)
Reference 7.6-42.6 pg/mL
http://loinc.org · 2243-4
S 2026-04-28 Lutropin [Units/volume] in Serum or Plasma 0.9 m[IU]/mL (low)
Reference 1.7-8.6 m[IU]/mL
http://loinc.org · 10501-5
S 2026-06-09 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 12 http://loinc.org · 44261-6
S 2026-06-09 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 6 http://loinc.org · 70274-6
S 2026-06-09 Testosterone [Mass/volume] in Serum or Plasma 238 ng/dL (low)
Reference 264-916 ng/dL
http://loinc.org · 2986-8
S 2026-06-09 Estradiol (E2) [Mass/volume] in Serum or Plasma 26 pg/mL
Reference 7.6-42.6 pg/mL
http://loinc.org · 2243-4
S 2026-06-09 Lutropin [Units/volume] in Serum or Plasma 2.4 m[IU]/mL
Reference 1.7-8.6 m[IU]/mL
http://loinc.org · 10501-5
S 2026-06-09 Follitropin [Units/volume] in Serum or Plasma 3.1 m[IU]/mL
Reference 1.5-12.4 m[IU]/mL
http://loinc.org · 15067-2
S 2026-06-09 Prolactin [Mass/volume] in Serum or Plasma 12.4 ng/mL
Reference 4-15.2 ng/mL
http://loinc.org · 2842-3
S 2026-06-09 Hemoglobin [Mass/volume] in Blood 13.6 g/dL
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 2026-08-04 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 7 http://loinc.org · 44261-6
S 2026-08-04 Testosterone [Mass/volume] in Serum or Plasma 452 ng/dL
Reference 264-916 ng/dL
http://loinc.org · 2986-8
S 2026-08-04 Lutropin [Units/volume] in Serum or Plasma 4.8 m[IU]/mL
Reference 1.7-8.6 m[IU]/mL
http://loinc.org · 10501-5
S 2026-08-04 Follitropin [Units/volume] in Serum or Plasma 5.2 m[IU]/mL
Reference 1.5-12.4 m[IU]/mL
http://loinc.org · 15067-2
S 2026-08-04 Hemoglobin [Mass/volume] in Blood 14.4 g/dL
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 2026-10-06 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2026-10-06 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 http://loinc.org · 70274-6
S 2026-10-06 Testosterone [Mass/volume] in Serum or Plasma 536 ng/dL
Reference 264-916 ng/dL
http://loinc.org · 2986-8
S 2026-10-06 Estradiol (E2) [Mass/volume] in Serum or Plasma 24 pg/mL
Reference 7.6-42.6 pg/mL
http://loinc.org · 2243-4
S 2026-10-06 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 38 ng/mL
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-10-20 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 2026-10-20 Total score [AUDIT-C] 2 http://loinc.org · 75626-2
S 2026-10-20 Cholesterol [Mass/volume] in Serum or Plasma 182 mg/dL
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-10-20 Cholesterol in HDL [Mass/volume] in Serum or Plasma 62 mg/dL
Reference >=40 mg/dL
http://loinc.org · 2085-9
S 2026-10-20 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 104 mg/dL
Reference <=129 mg/dL
http://loinc.org · 13457-7
S 2026-10-20 Triglyceride [Mass/volume] in Serum or Plasma 80 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-04-14Body height178 cm8302-2S
2026-04-14Body weight71.4 kg29463-7S
2026-04-14Body mass index (BMI) [Ratio]22.5 kg/m239156-5S
2026-04-14Systolic blood pressure122 mm[Hg]8480-6S
2026-04-14Diastolic blood pressure76 mm[Hg]8462-4S
2026-04-14Heart rate64 /min8867-4S
2026-04-14Respiratory rate14 /min9279-1S
2026-04-14Body temperature36.6 Cel8310-5S
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-04-28Body height178 cm8302-2S
2026-04-28Body weight71 kg29463-7S
2026-04-28Body mass index (BMI) [Ratio]22.4 kg/m239156-5S
2026-04-28Systolic blood pressure120 mm[Hg]8480-6S
2026-04-28Diastolic blood pressure74 mm[Hg]8462-4S
2026-04-28Heart rate62 /min8867-4S
2026-04-28Respiratory rate14 /min9279-1S
2026-04-28Body temperature36.5 Cel8310-5S
2026-04-28Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-06-09Body height178 cm8302-2S
2026-06-09Body weight70.1 kg29463-7S
2026-06-09Body mass index (BMI) [Ratio]22.1 kg/m239156-5S
2026-06-09Systolic blood pressure118 mm[Hg]8480-6S
2026-06-09Diastolic blood pressure74 mm[Hg]8462-4S
2026-06-09Heart rate58 /min8867-4S
2026-06-09Respiratory rate14 /min9279-1S
2026-06-09Body temperature36.6 Cel8310-5S
2026-06-09Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-08-04Body height178 cm8302-2S
2026-08-04Body weight69.3 kg29463-7S
2026-08-04Body mass index (BMI) [Ratio]21.9 kg/m239156-5S
2026-08-04Systolic blood pressure124 mm[Hg]8480-6S
2026-08-04Diastolic blood pressure78 mm[Hg]8462-4S
2026-08-04Heart rate60 /min8867-4S
2026-08-04Respiratory rate14 /min9279-1S
2026-08-04Body temperature36.7 Cel8310-5S
2026-08-04Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-10-06Body height178 cm8302-2S
2026-10-06Body weight68.6 kg29463-7S
2026-10-06Body mass index (BMI) [Ratio]21.7 kg/m239156-5S
2026-10-06Systolic blood pressure118 mm[Hg]8480-6S
2026-10-06Diastolic blood pressure72 mm[Hg]8462-4S
2026-10-06Heart rate54 /min8867-4S
2026-10-06Respiratory rate14 /min9279-1S
2026-10-06Body temperature36.6 Cel8310-5S
2026-10-06Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-08-25Body height178 cm8302-2S
2026-08-25Body weight69 kg29463-7S
2026-08-25Body mass index (BMI) [Ratio]21.8 kg/m239156-5S
2026-08-25Systolic blood pressure126 mm[Hg]8480-6S
2026-08-25Diastolic blood pressure78 mm[Hg]8462-4S
2026-08-25Heart rate70 /min8867-4S
2026-08-25Respiratory rate14 /min9279-1S
2026-08-25Body temperature36.7 Cel8310-5S
2026-08-25Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-10-20Body height178 cm8302-2S
2026-10-20Body weight68.5 kg29463-7S
2026-10-20Body mass index (BMI) [Ratio]21.6 kg/m239156-5S
2026-10-20Systolic blood pressure116 mm[Hg]8480-6S
2026-10-20Diastolic blood pressure72 mm[Hg]8462-4S
2026-10-20Heart rate54 /min8867-4S
2026-10-20Respiratory rate14 /min9279-1S
2026-10-20Body temperature36.6 Cel8310-5S
2026-10-20Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Structured safety assessment

Current ideation
absent
Intent
absent
Plan
absent
Disposition
Outpatient care with a collaborative safety plan, the 988 Suicide & Crisis Lifeline, and a two-week follow-up

This assessment is synthetic and does not convert historical behavior into a present-day fact.

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
Testosterone, LH, and FSH back in the reference range within six months of the last estrogen dose, without testosterone therapy2026-08-04completedTestosterone 452 ng/dL with normal LH and FSH at sixteen weeks
Breast tenderness gone and gynecomastia reduced; a surgical opinion offered if it persists and troubles him2026-10-06activeTenderness gone by six months; small residual glandular tissue; watchful waiting to twelve months
Depression response (PHQ-9 down by at least 50 percent) by sixteen weeks, then remission (PHQ-9 below 5)2026-10-06completedPHQ-9 7 at sixteen weeks (down 53 percent) and 4 at six months
Back to running about 40 km a week and changing at his club again2026-10-06completedRunning 40 km a week and back with the club by six months

Interventions

InterventionStatusGuideline
Consent first: every examination, test, and treatment is explained and offered, and he may decline any of it; intimate examinations only with his agreement at each step and with a chaperone offered. The estrogen he was given as a condition of avoiding prison was not freely consented treatment, and no further doses will be givencompletedGL-APA-SM-2021, GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018
Gynecomastia workup: breast and testicular examination; testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests today; scrotal ultrasound; breast ultrasound only if the examination becomes equivocalcompletedGL-EAA-GM-2019, GL-ES-HYPOGONAD-2018
Endocrinology consultation to confirm that the estrogen explains the findings and to advise on recovery of the gonadal axis, testosterone therapy, bone health, and surgerycompletedGL-EAA-GM-2019, GL-ES-HYPOGONAD-2018
Watchful waiting for the gynecomastia after the estrogen stops; testosterone, estradiol, LH, and FSH every six to eight weeks until normal; no testosterone therapy while the axis is recovering; a surgical opinion if gynecomastia persists about twelve months and troubles himcompletedGL-EAA-GM-2019, GL-ES-HYPOGONAD-2018
Bone health: vitamin D replacement, calcium from food, continued running and strength work; bone density scan only if hypogonadism persists beyond six months or a fracture occurscompletedGL-EAA-GM-2019, GL-ES-HYPOGONAD-2018, GL-ES-OSTEO-MEN-2012
Weekly psychotherapy with a gay-affirming clinic psychologist for about 16 sessions, addressing the prosecution, the coerced treatment, and minority stress; an antidepressant offered and declined for now, to be reconsidered if the PHQ-9 has not fallen by half at about eight weekscompletedGL-MDD-2022, GL-CMID-2026, GL-APA-SM-2021
Collaborative safety plan with warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; suicide-risk review and PHQ-9 at every visitcompletedGL-SUICIDE-2024, GL-CMID-2026
Sexual health as routine adult care: HIV and STI testing and a PrEP discussion offered at his preventive visit, with his consent; libido and erectile function reviewed as testosterone recoverscompletedGL-CDC-STI-2021, GL-USPSTF-PREP-2023, GL-APA-SM-2021
Affirming practice: his orientation, name, and pronouns recorded as he chooses; his records shared only with his consent; a written letter from this clinic, at his request, confirming that the estrogen he was given was not medically indicatedcompletedGL-APA-SM-2021
Add bupropion XL 150 mg each morning, chosen by him after an informed discussion of options and side effects; nurse telephone check at two weeks; PHQ-9 and blood pressure at each visitcompletedGL-CMID-2026, GL-MDD-2022

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) Andrew Hodges, The Alan Turing Home Page biography
SRC-0002 Hodges A. The Alan Turing Internet Scrapbook: Defiant until death Andrew Hodges, The Alan Turing Home Page biography
SRC-0003 O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics University of St Andrews biography
SRC-0004 Hodges A. The Alan Turing Internet Scrapbook: Non-linear Life Andrew Hodges, The Alan Turing Home Page biography
SRC-0005 Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 BBC News other
SRC-0006 Royal pardon for WW2 code-breaker Dr Alan Turing UK Ministry of Justice (GOV.UK) government
SRC-0007 Gordon Brown issues apology for treatment of Alan Turing The University of Manchester other
SRC-0008 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the gynecomastia workup and watchful waiting, recovery of the gonadal axis without testosterone therapy, the bone-health plan, the depression treatment and safety review at every visit, routine sexual health care, and the recorded deviation.
provenance reviewnot_startedHodges's biography pages, MacTutor, a BBC report, a GOV.UK press release, and a University of Manchester news item logged. The prosecution, the hormone treatment, Jungian analysis, and the death and verdict are D; depression and both readings of his death are R. The tablet-and-implant account of the treatment was not verified.
safe messaging reviewnot_startedSafety assessment is synthetic with no current ideation; the disputed circumstances of his death are recorded only as history, in plain terms and without method detail, and are not echoed in the modern episode. Sexual orientation is recorded respectfully and never as a problem.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.